Discussing the management of Hormone Receptor Positive Breast Cancer
Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding the adjuvant abemaciclib approval where one doesn’t need Ki-67 levels anymore, and new agents recently approved by the FDA – elacestrant, TDXD and sacituzumab providing more treatment options for our patients.